Find a Faculty

Gold Divider 4Col
Physician Photo

Business Offices

Address
Box 1020, Mount Sinai School of Medicine
One Gustave L. Levy Place
New York , NY 10029
Tel
212-241-4160
Address
Annenberg Building Floor 25th Floor Room 70A
1468 Madison Avenue
New York, NY 10029
Tel
212-741-4160
Fax
212-860-9279
Address
Annenberg Building Floor 25 Room 70
1468 Madison Avenue
New York, NY 10029
Tel
212-241-4160
Address
Annenberg Building Floor 25 Room 270, 275
1468 Madison Avenue
New York, NY 10029
Tel
212-241-3397

Xiajun (John) Li

ASSISTANT PROFESSOR  Developmental and Regenerative Biology
ASSISTANT PROFESSOR  Oncological Sciences

Overview

Gender Male
E-mail xiajun.li@mssm.edu
Education and Training B.S., Peking (Beijing) University
  Ph.D., Columbia University
  Postdoctoral Training, Harvard Medical School

Department of Developmental and Regenerative Biology

Training

Education and Training B.S., Peking (Beijing) University
  Ph.D., Columbia University
  Postdoctoral Training, Harvard Medical School

Research

Specific Clinical/Research Interests: Acquisition and maintenance of DNA methylation genomic imprints; Epigenetic regulation in stem cells; Maintenance and differentiation of embryonic stem cells; LIN-12/Notch signaling and cardiovascular development.

Postdoctoral Fellows: Xiaopan Zuo, Jipo Sheng

Research Personnel: Monica Andrade

Summary of Research Studies:
Genomic imprinting is essential for mammalian development. Consistent with this, a majority of cloned embryos die in utero, mainly from the failure to re-establish proper genomic imprints. Cell-based therapies offer great hopes for various degenerative diseases, including Alzheimer's disease and diabetes. Embryonic stem (ES) cells derived from nuclear transfer experiments and induced pluripotent stem (iPS) cells reprogrammed from adult cells are candidates for this therapeutic approach. However, they all have genomic imprinting defects which can inhibit differentiation and may even cause cancer. Therefore, a requirement for attaining properly differentiated cell lineages for therapeutic applications is a thorough understanding of the underlying mechanisms of genomic imprinting. Despite that genomic imprinting was identified in mammals almost three decades ago, many unanswered questions persist about the nature of genomic imprinting memory and about how genomic imprints are established and maintained. Recently, we discovered Zfp57 in a screen for ES cell-specific genes. Zfp57 encodes a KRAB zinc finger protein and exhibits maternal-zygotic embryonic lethality in mouse, the first one identified in mammals. ZFP57 is a key regulator in genomic imprinting at three different phases: establishment, maintenance and re-acquisition of DNA methylation imprints. Consistent with our finding, mutations in human Zfp57 result in hypomethylation at multiple imprinted regions. ZFP57 maintains both paternal and maternal genomic imprints and may target DNA methyltransferases to the imprinting control regions (ICR).

Interestingly, these germline-derived differential DNA methylation imprints at the ICRs can be lost in embryos in the absence of both maternal and zygotic Zfp57 and they can be acquired in mouse embryos in the presence of zygotic Zfp57 even though they are not established in the germline. Moreover, acquisition of DNA methylation in mouse embryos occurs in an allele-specific fashion, suggesting the presence of DNA methylation-independent heritable imprinting memory. Therefore, further functional analysis of ZFP57 in genomic imprinting will help us to achieve better understanding of the molecular nature of imprinting memory as well as the temporal and developmental control of DNA methylation imprints. To gain insights into the underlying molecular mechanisms of establishment, maintenance and acquisition of DNA methylation genomic imprints, we have identified some ZFP57-associated proteins through co-immunoprecipitation coupled with mass spectrometry. We are in the process of verifying their interactions with ZFP57. Then we will characterize their functions in ES cells as well as in mouse embryos with respect to DNA methylation in genomic imprinting. The approaches we are undertaking are either through gene targeting or RNAi knockdown to reduce or eliminate the functions of a target gene. Dysregulation of imprinting genes can lead to cancer, neurological diseases, diabetes and other kinds of human diseases. Indeed, mutations in human ZFP57 are associated with transient neonatal diabetes and congenital heart defects. We have independently discovered that Zfp57 mutant mouse also display defects in the cardiovascular system. Thus, our mutant mouse could serve as a good animal model for analyzing imprinting-related human diseases.

Publications

Li X, Ito M, Zhou F, Youngson N, Zuo X, Leder P, Ferguson-Smith A. A maternal-zygotic effect gene, Zfp57, maintains both maternal and paternal imprints. Developmental Cell 2008; 15: 547-557.


Li X, Leder P. Identifying genes preferentially expressed in undifferentiated embryonic stem cells. BMC Cell Biology 2007; 8(1): 37.


Institutes, Centers, Programs and Laboratories

The Mount Sinai Medical Center is home to an extensive array of top-notch research centers and laboratories, where scientists and researchers work to translate the rapid advances in basic science into the innovative patient care for which we are known.

Clinical Trials

Participating in Mount Sinai’s clinical trials allows you to take advantage of innovative treatments as we work together to advance the future of medicine.

(800) MD-SINAI (800) 637-4624

Visit Mount Sinai Queens